No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk Patients Identified Through ctDNA-based MRD Assessment After CRC Resection By Ogkologos - June 22, 2026 53 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR European Lung Cancer Congress 2024 March 7, 2024 Mutational Patterns Drive Metastatic Aggressiveness of Appendiceal Adenocarcinomas December 21, 2022 Greater OS Benefit Among Patients with Advanced Cancer Treated with Matched... November 11, 2024 Colposcopia: Cómo prepararse y qué saber August 6, 2020 Load more HOT NEWS What Is Peripheral Neuropathy and How Can It Be Prevented or... EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin and Pembrolizumab Community Comes Together To Give Terminally Ill Father One Last Christmas... Can Being Exposed to Wildfire Smoke Affect Your Cancer Risk?
